International Cannabis Provides Danish Cultivation, Construction, GMP Certification and Genetics Updates
VANCOUVER, British Columbia, Dec. 19, 2018 (GLOBE NEWSWIRE) — ICC International Cannabis Corp. (CSE: WRLD)(FWB: 8K51)(OTC: KNHBF) (“ICC” or “International Cannabis” or the “Company”) is pleased to provide the following material progress updates pertaining to its Danish medical Cannabis operations:
- Expansion of its Danish land parcel to 100 acres;
- Engagement of leading greenhouse engineering and manufacturing firm, Azrom (https://azrom.com/);
- Finalization of project plan and submission of building permits;
- Land development and infrastructure operations;
- Construction and validation of its planned GMP manufacturing facility;
- Continued augmentation of its seed/strain catalogue; and
- Establishment of genetics room and completion of successful test sprouts.
International Cannabis controls a medical Cannabis cultivation and manufacturing licence in the Kingdom of Denmark (see ICC news release dated September 27, 2018). The Company’s Danish assets mirror industry peers such as Canopy Growth Corp., Green Organic Dutchman Holdings, Aurora Cannabis Inc. and CannTrust Holdings.
International Cannabis has engaged an Israeli cannabis organic cultivation and management company, Sababa Sciences Inc. (“Sababa”) to assist with the build out of its Danish medical Cannabis cultivation facility. Sababa will provide end-to-end management, including the implementation of advanced Israeli agricultural technologies for high-quality medical cannabis treatments.
FACILITY DESIGN AND CONSTRUCTION
International Cannabis has increased its Danish land holdings and now controls a 100-acre property located in the municipality of Moeldrup. Initial development work, as well as the adaptation of infrastructure for the property is scheduled to commence in January of 2019. The land parcel has favourable lease terms and is equipped with necessary utilities including water, gas, telecommunications and electricity.
Stage A of International Cannabis’ Danish medical Cannabis facility will include a 49,600 square foot cultivation unit, an administrative area, as well as a production and processing structure. All structures scheduled for construction been designed to comply with European GMP standards.
International Cannabis has engaged leading greenhouse engineering and manufacturing firm, Azrom (https://azrom.com/) to assist facility engineering planning initiatives. Azrom is a leader in the global agricultural market, and specializes in the design, engineering and manufacturing of customized greenhouses solutions. Under Sababa’s guidance, Azrom will provide end-to-end planning and consulting services throughout the build out of International Cannabis’ Danish medical Cannabis cultivation facility.
International Cannabis forecasts its initial greenhouse engineering planning initiatives will be completed by December 31, 2018. The Company also expects to receive the final pricing proposals for greenhouse construction and growing systems by the end of 2018. Once finalized, delivery of the greenhouse structure and the required growing systems is estimated for the end of the first quarter of 2019.
Upon delivery, the Company has budgeted 90 days for implementation and installation of the greenhouse structure and growing systems.
LAND DEVELOPMENT AND PERMITTING
International Cannabis’ Danish operations are strategically located along a national highway in western Denmark, permitting direct access to the Danish capital of Copenhagen. Western Denmark is a region known for its highly educated and skilled labour force, and robust agriculture community.
International Cannabis is in the process of applying for building permits, which will extend to three cultivation units, an administrative area, production and processing structures, as well as a GMP manufacturing area. The Company’s architects and engineers are presently finalizing the project plan for its Danish cultivation facilities, and will manage the receipt of building permit from the local authorities. The Company expects to successfully receive its final building permits by February 1, 2019.
Concurrent with the building permitting process, International Cannabis will initiate land development and infrastructure work on its 100-acre land parcel. The Company’s land development and infrastructure campaign includes:
- Completion of a mandatory Museum/Archeological Survey;
- Removal of trees, shrubs and bushes;
- Leveling of the construction area; and
- Installation of temporary modular housing. The temporary modular housing will act as a command centre and office for construction and engineering staff, throughout the land development and infrastructure operations.
International Cannabis forecasts the completion of its land development and infrastructure initiatives by February 1, 2019.
Eugene Beukman, chief executive officer and a director of International Cannabis, stated: “International Cannabis continues to make material progress towards a world-class cultivation facility in Denmark. Through its partnerships with Sababa and Azrom, the Company is working with world-renowned experts in greenhouse engineering, manufacturing and construction. We holds claim to a premier European cannabis asset, domiciled in a jurisdiction with a highly skilled agriculture and manufacturing work force. The Company has laid the ground work for a very successful 2019 and looks forward to operating its state of the art Danish cannabis operations”.
International Cannabis is also pleased to report it has finalized the design of its European GMP compliant manufacturing facility. The Company’s GMP manufacturing facility will be constructed and operated by Relief Aps, a subsidiary of Sababa.
International Cannabis is currently assessing bids from contractors and suppliers for the construction of its GMP manufacturing facility and is evaluating leveraging modular structures to accelerate time to market. The Company will begin construction of its GMP facility during the second quarter of 2019, and is hopeful to obtain GMP validation prior to the end of 2019.
GENETIC AND STRAIN CATALOGUE
International Cannabis continues to bolster its genetic and strain catalogue, through the purchase 10 varieties of seeds from several different suppliers. The Company has also successfully established a genetics room in accordance with industry best practices. The genetics rooms is monitored and operated by Sababa’s agronomy team. With the assistance of Sababa, International Cannabis has completed initial sprouts of the seeds for testing and research purposed.
International Cannabis now has access to 130 laboratory-tested craft cannabis strains. These unique craft strains will allow for the continued differentiation of the International Cannabis brand, in an increasingly generic and homogenized market. International Cannabis plans to continue to augment its catalogue of top-ranked strains from around the world.
Finished cannabis and cannabis derivatives produced by International Cannabis will eventually be sold through Denmark’s retail pharmacy network. The Kingdom of Denmark has developed a program for reimbursement for Cannabis therapeutics through its national health care program. Patients can be reimbursed for their Cannabis medicine in the same manner as all other prescriptions. International Cannabis’ Danish assets are positioned in immediate proximity to Germany, allowing for direct imports of CBD (cannabidiol) products, as well as medical Cannabis flower.
ICC International Cannabis, through its subsidiaries, has agreements in place for European-based pharmaceutical distribution, wholesale importation, and research and development, as well as licences to cultivate, produce, distribute, store and export cannabis, cannabis derivatives and industrial hemp in Colombia, Denmark, Poland, Greece, Portugal, South Africa and the Kingdom of Lesotho.
ON BEHALF OF THE ICC INTERNATIONAL CANNABIS CORP BOARD OF DIRECTORS
+1 (604) 687-2038
Learn more about ICC by visiting our website at: https://intlcannabiscorp.com/
Stay up to date with everything happening at ICC by following or liking us on:
Facebook – https://www.facebook.com/ICCWRLD/
Twitter – https://twitter.com/ICC_WRLD
LinkedIn – https://www.linkedin.com/company/icc-wrld/
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Notice Regarding Forward Looking Information:
This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: political changes in Canada and internationally, future legislative and regulatory developments involving cannabis in Canada and internationally, the Company’s ability to secure distribution channels in international jurisdictions, competition and other risks affecting the Company in particular and the cannabis industry generally.
The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward- looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.